U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167251) titled 'Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids' on Aug. 25.
Brief Summary: This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors. It aims to determine whether of 0.5-1miligram per kilogram bodyweight prednisolone is sufficient to manage immune-related hepatitis without the need for dose escalation or additional immunosuppressive therapy.
Study Start Date: Aug. 25
Study Type: OBSERVATIONAL
Condition:
Immune Related Adverse Events
Immune-Mediated Hepatitis
Cancer
In...